Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.
Purity:
>95%
CAS Number:
[2329669-72-7]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted
